COHANCE

Cohance Lifesciences share price & results

Cohance Lifesciences Limited· Healthcare

Hyderabad-based CDMO making pharma intermediates, APIs, ADC payloads & oligonucleotides for global innovators.

₹451.6 −1.31%
MCap ₹17.8k Cr Price to earnings (TTM to Sept 2026) 366.83× Return on equity (TTM to Sept 2026) 1.24%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day COHANCE alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
COHANCE at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

2 of 15 judged targets kept · 14 open · verdicts reflect calls analysed to Q2 FY27.

Cohance Lifesciences Limited management guidance track record on Inve: 29 targets tracked across analysed earnings calls (2 achieved, 13 missed, 14 open).

Watch execution in Growth & Demand (1 achieved · 2 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Growth API Product Validations
7 to 8 new validations
Q1 FY26
Q2 FY27:FY26 is complete. The target was achieved.
Achieved
Growth Total Revenue
$1 billion by FY30
Q3 FY25
Q2 FY27:Not addressed.
Ghosted
Growth ADC Supply Capability
Phase 2B by FY27 end
Q3 FY26
Q2 FY27:Management confirmed bioconjugation capacity expansion remains on track for commercial availability by early FY2028, extending the Phase 2B delivery timeline past FY27 end.
Delayed

Source: Inve Guidance Tracker for Cohance Lifesciences Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

13 of Cohance Lifesciences Limited's 29 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 26 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 6 Nov 2026

Q2 FY27: Cohance Lifesciences Limited Q2 FY27

Cohance Lifesciences delivered sequential operating recovery in Q2 FY27, with revenue growing 13% QoQ to INR 4,767 million and adjusted EBITDA margins expanding to 10%. Growth was supported by a 34.5% sequential rebound in Pharma CDMO and steady 5% YoY growth in API+, though Specialty Chemicals faced headwinds from generic AgChem destocking. Management reiterated expectations of YoY growth in revenue and EBITDA for H2 FY27, backed by new commercial wins and order reloads, while actively addressing regulatory and CAPA matters including USFDA inspection responses and the Suryapet closure notice.

What management highlighted

  • Revenue rose 13% sequentially to INR 4,767 million, while adjusted EBITDA expanded from INR 92 million to INR 458 million (10% margin)
  • Pharma CDMO registered a sequential revenue rebound of 34.5% QoQ driven by small molecules
  • Sapala oligo franchise continued robust momentum, growing 33.6% YoY in Q2 and 83% YoY in H1 FY27

Source: Inve analysis of Cohance Lifesciences Limited’s Q2 FY27 earnings call · to 6 Nov 2026

Compare across 9 analysed calls

Price & Snapshot

₹451.6 −1.31% · −₹6

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance −26.6% 1Y

₹300₹400₹500₹600Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q3 FY26 — 12 Feb 2026Q4 FY26 — 12 May 2026Q1 FY27 — 5 Aug 2026Q2 FY27 — 6 Nov 2026

1Y: ₹615.5 on 14 Nov 2025 → ₹451.6. High ₹615.5 (14 Nov 2025), low ₹279.9 (6 Mar 2026).

Previous close
₹457.6
Market cap
₹17.8k Cr
52-week range
₹279.9 – ₹611.45
One year
−26.14%
Price to earnings (TTM to Sept 2026)
366.83×
Return on equity (TTM to Sept 2026)
1.24%

Reported

Key financial metrics & valuation ratios

Revenue: 477 ₹ crore (−14.2% YoY) · Net profit: 2.3 ₹ crore (−96.6% YoY) · Return on equity: 1.24 % (−11.1 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue477 ₹ crore−14.2% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin7.4 %−14.3 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit2.3 ₹ crore−96.6% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity1.24 %−11.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.45 %−6.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-21.32 %−161.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Sector context

Sector call context

Shared sector pressures matched to this company’s latest reporting period.

Similar pressures reported by peers

Tailwind coverage is not available yet.
  • Audits completed at Pashamylaram, Shamshabad, and Jaggayyapeta with CAPA responses…

    53 other companies · Regulatory policy · Q2 FY27
  • Full-year FY27 Specialty Chemicals revenue guidance was cut from broadly flat to a…

    9 other companies · Pricing discipline · Q2 FY27
  • Continued destocking across two established commercial ADC programs softened near-term…

    2 other companies · Customer inventory · Q2 FY27

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:COHANCE
Exchange
NSE
Currency
INR

What Cohance Lifesciences Limited does

Sourced to annual report & earnings calls.

Cohance Lifesciences (formerly Suven Pharmaceuticals) is a Hyderabad-headquartered contract development and manufacturing organisation (CDMO) that custom-synthesises pharmaceutical intermediates, active pharmaceutical ingredients (APIs), antibody-drug-conjugate (ADC) payloads/linkers and oligonucleotide building blocks for global innovator pharma, biotech and specialty-chemical customers, earning fee-for-service and scale-up manufacturing income rather than selling its own branded drugs. It operates through three business units - Pharma CDMO, API+ and Specialty Chemicals - spanning drug discovery support through commercial-scale manufacturing. Its acquisitions of NJ Bio (a Princeton, NJ-based ADC specialist) and Sapala (an oligonucleotide building-blocks maker) extended its capabilities into next-generation biologic modalities alongside its India manufacturing base.

Segments

  • Pharma CDMO
  • API+
  • Specialty Chemicals
Manufacturing plants
14
R&D facilities
7
R&D scientists
510+
Installed manufacturing capacity
3,500 KL
Commercial patented molecules (Pharma CDMO)
16
Customer base
Works with 19 of the top 20 global innovator pharma companies
Headquarters Hyderabad, India

How the price took the results

Moved an average of ±1.9% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY276 Nov 26477 2−14.2%₹449 → ₹433.55−3.4%
Q1 FY275 Aug 26422 -45−23.1%₹424.9 → ₹429.45+1.1%
Q4 FY2612 May 26619 8−26.3%₹476.7 → ₹484.65+1.7%
Q3 FY2612 Feb 26545 29−19.5%₹355.25 → ₹350.75−1.3%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Cohance Lifesciences Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Cohance Lifesciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Keep reading

Other Healthcare companies

PEER COMPARISON
Median ₹17,758 Cr Mkt Cap
₹0 Cr₹10,000 Cr₹20,000 Cr₹30,000 CrCohance Lifesciences Limited (COHANCE): ₹17,758 Cr₹17,758 CrCOHANCEShilpa Medicare Limited (SHILPAMED): ₹18,270 Cr₹18,270 CrSHILPAMEDAlivus Life (ALIVUS): ₹18,207 Cr₹18,207 CrALIVUSOnesource Specialty Pharma Limited (ONESOURCE): ₹17,936 Cr₹17,936 CrONESOURCESyngene International Limited (SYNGENE): ₹17,810 Cr₹17,810 CrSYNGENEDr. Agarwal's Health Care Limited (AGARWALEYE): ₹17,569 Cr₹17,569 CrAGARWALEYEPfizer Limited (PFIZER): ₹17,470 Cr₹17,470 CrPFIZERCaplin Point Laboratories Limited (CAPLIPOINT): ₹17,111 Cr₹17,111 CrCAPLIPOINTMOLBIO (MOLBIO): ₹17,055 Cr₹17,055 CrMOLBIO

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Cohance Lifesciences Limited

Compiled directly from COHANCE's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Cohance Lifesciences Limited (COHANCE) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Cohance Lifesciences Limited reported revenue of ₹477 Cr, net profit of ₹2 Cr, an operating margin of 7.4%. Diluted earnings per share stood at ₹0.4.

How is Cohance Lifesciences Limited (COHANCE) valued today, and what growth does the stock price imply?

Cohance Lifesciences Limited (COHANCE) trades at ₹451.6, with a market capitalization of ₹17.8k Cr, a trailing P/E multiple of 366.83×, return on equity (ROE) of 4.89%, ROCE of 5.80%.

Did Cohance Lifesciences Limited (COHANCE) management keep or miss its earnings call guidance?

Across 29 management guidance targets tracked from Cohance Lifesciences Limited's earnings calls, 2 were achieved, 13 missed, and 14 remain open (13% delivered among resolved targets). Sampled guidance includes API Product Validations: "7 to 8 new validations" (stated in Q1 FY26, current status: achieved).

Who owns Cohance Lifesciences Limited (COHANCE) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 57.5%, FIIs hold 7.7%, DIIs hold 18.9%, Public shareholders hold 15.9%.

What did Cohance Lifesciences Limited (COHANCE) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Nov 2026) concall, Cohance Lifesciences delivered sequential operating recovery in Q2 FY27, with revenue growing 13% QoQ to INR 4,767 million and adjusted EBITDA margins expanding to 10%. Growth was supported by a 34.5% sequential rebound in Pharma CDMO and steady 5% YoY growth in API+, though Specialty Chemicals faced headwinds from generic AgChem destocking. Management reiterated expectations of YoY growth in revenue and EBITDA for H2 FY27, backed by new commercial wins and order reloads, while actively addressing regulatory and CAPA matters including USFDA inspection responses and the Suryapet closure notice. Read Cohance Lifesciences Limited Q2 FY27 concall summary →